Health Care Technology
Company Overview of WellDoc, Inc.
WellDoc, Inc. is a health care behavioral science and technology company that develops technology solutions to support chronic disease management. It provides DiabetesManager, an intelligent, data driven, and patient centric platform that enables patients and health care providers to coordinate diabetes care, propel self-management, and achieve long-term adherence. The company’s DiabetesManager platform features personalized and real-time patient coaching, testing and medication reminders, out of bound alerts, and metabolic target ranges; family and community connectivity, and caregiver alerts and support; cloud-based analytics, evidence-based guidelines, longitudinal tracking, and event/ale...
1501 Saint Paul Street
Baltimore, MD 21202
Founded in 2005
Key Executives for WellDoc, Inc.
Co-Founder and Chief Medical Officer
Vice President of Operations
Compensation as of Fiscal Year 2014.
WellDoc, Inc. Key Developments
WellDoc and American Diabetes Association's Maryland Chapter Announce New Collaboration to Empower People with Type 2 Diabetes to Manage its Condition
Sep 16 14
The American Diabetes Association (ADA) Maryland Chapter and WellDoc(R) have announced the launch of a collaboration to empower people in Maryland with type 2 diabetes to take control of their diabetes by improving their day-to-day self-management. This announcement marks the beginning of the collaboration between WellDoc and ADA, with many activities to come throughout 2014 and 2015. WellDoc developed BlueStar(R), the first-of-its-kind Mobile Prescription Therapy cleared by the FDA and available only by prescription. BlueStar provides patients real-time guidance to improve their diabetes self-management, as well as, clinical decision support to help their doctor optimize their diabetes treatment plan. BlueStar provides personalized healthcare advice that other products cannot provide without the supervision of a licensed healthcare provider. Further, the National ADA recognizes BlueStar on its website as the first and only in the new class of diabetes treatment known as Mobile Prescription Therapy. At the state level, WellDoc will interact directly with Maryland residents and provide them with educational resources about type 2 diabetes. WellDoc's educational booth will appear at the Baltimore Step Out Walk on October 5 and the Frederick Step Out Walk on October 12, and plans are underway to support American Diabetes Month in November.
WellDoc Improves Hypoglycemia Prediction Model for Patients with Type 2 Diabetes
Jun 16 14
Researchers at WellDoc(R) presented updated results of its hypoglycemia prediction technology at this week's 2014 American Diabetes Association 74th Scientific Sessions. WellDoc announced an enhanced model that incorporates both glucose and medication data has demonstrated the ability to predict hypoglycemia within a specific hour. Hypoglycemia is one of the most dangerous, costly, and difficult diabetes complications to manage. A recent study of 2.4 million type 2 diabetes patients found that hypoglycemia was especially common in patients treated with insulin or sulfonylureas with costs for a hypoglycemia-related hospital event averaging $10,362, regardless of a patient's drug regimen. A 2005 study further reported that patients who had experienced hypoglycemia had 77% more disability days per year. Using the new methodology, the model also could accurately predict the hour of the hypoglycemia event over the next day when the patients medication information is known. WellDoc intends to incorporate the hypoglycemia prediction algorithms into BlueStar(TM), the mobile prescription therapy for adults with type 2 diabetes. Once incorporated, BlueStar's automated, real-time coaching will educate a patient about how to best manage and avoid hypoglycemia.
WellDoc, Inc. Announces Board Changes
Mar 13 14
WellDoc, Inc. announced that Kevin P. McRaith has joined the Company as President. Mr. McRaith most recently held the position of Vice President, Sales & Marketing at Human Genome Sciences and held similar leadership roles at Genentech and Abbott after starting his career at Baxter Healthcare. He will report to Ryan Sysko, CEO of WellDoc. Mr. McRaith has more than 20 years of experience commercializing therapies for oncology, immunology, HIV, oncology, CNS and cardiology most recently with Human Genome Sciences. Prior to that McRaith was the Vice President, Sales and Marketing for Genentech's Hematology Franchise, where he led the commercial efforts for the top-selling biologic, Rituxan (rituximab). In conjunction with this move, current President, Dr. Anand K. Iyer, will assume a new role of Chief Data Science Officer. With a dissertation in pattern recognition from Carnegie Mellon University, he will accelerate enhancements to WellDoc's analytics engine and predictive modeling capabilities.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 26, 2014